Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Kindeva Drug Delivery
Deal Size : Undisclosed
Deal Type : Agreement
Kindeva and BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Details : Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 12, 2020
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Kindeva Drug Delivery
Deal Size : Undisclosed
Deal Type : Agreement